Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A

por Whelan, Kathryn T., Pathan, Ansar A., Sander, Clare R., Fletcher, Helen A., Poulton, Ian, Alder, Nicola C., Hill, Adrian V. S., McShane, Helen
Publicado 2009

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A

por Whelan, Kathryn T., Pathan, Ansar A., Sander, Clare R., Fletcher, Helen A., Poulton, Ian, Alder, Nicola C., Hill, Adrian V. S., McShane, Helen
Publicado 2011

Th1/Th17 Cell Induction and Corresponding Reduction in ATP Consumption following Vaccination with the Novel Mycobacterium tuberculosis Vaccine MVA85A

por Griffiths, Kristin L., Pathan, Ansar A., Minassian, Angela M., Sander, Clare R., Beveridge, Natalie E. R., Hill, Adrian V. S., Fletcher, Helen A., McShane, Helen
Publicado 2011

Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials

por Pathan, Ansar A., Sander, Clare R., Fletcher, Helen A., Poulton, Ian, Alder, Nicola C., Beveridge, Natalie E. R., Whelan, Kathryn T., Hill, Adrian V. S., McShane, Helen
Publicado 2007

Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-β1

por Fletcher, Helen A., Pathan, Ansar A., Berthoud, Tamara K., Dunachie, Susanna J., Whelan, Kathryn T., Alder, Nicola C., Sander, Clare R., Hill, Adrian V.S., McShane, Helen
Publicado 2008

Correction: Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials

por Pathan, Ansar A., Sander, Clare R., Fletcher, Helen A., Poulton, Ian, Alder, Nicola C., Beveridge, Natalie E. R., Whelan, Kathryn T., Hill, Adrian V. S., McShane, Helen
Publicado 2011

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults

por Pathan, Ansar A., Minassian, Angela M., Sander, Clare R., Rowland, Rosalind, Porter, David W., Poulton, Ian D., Hill, Adrian V.S., Fletcher, Helen A., McShane, Helen
Publicado 2012

Introducing biomarkers for invasive fungal disease in haemato-oncology patients: a single-centre experience

por Martinelli, Anthony W., Wright, Callum B., Lopes, Marta S., Swayne, Rosemary L., Krishnamurthy, Pramila, Crawley, Charles, Uttenthal, Ben, Follows, George, Babar, Judith, Aliyu, Sani H., Enoch, David A., Sander, Clare R.
Publicado 2022

Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A

por Tanner, Rachel, Kakalacheva, Kristina, Miller, Ellen, Pathan, Ansar A, Chalk, Rod, Sander, Clare R, Scriba, Tom, Tameris, Michelle, Hawkridge, Tony, Mahomed, Hassan, Hussey, Greg, Hanekom, Willem, Checkley, Anna, McShane, Helen, Fletcher, Helen A
Publicado 2014

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults

por Minassian, Angela M, Rowland, Rosalind, Beveridge, Natalie E R, Poulton, Ian D, Satti, Iman, Harris, Stephanie, Poyntz, Hazel, Hamill, Matthew, Griffiths, Kristin, Sander, Clare R, Ambrozak, David R, Price, David A, Hill, Brenna J, Casazza, Joseph P, Douek, Daniel C, Koup, Richard A, Roederer, Mario, Winston, Alan, Ross, Jonathan, Sherrard, Jackie, Rooney, Guy, Williams, Nicola, Lawrie, Alison M, Fletcher, Helen A, Pathan, Ansar A, McShane, Helen
Publicado 2011